← Leaderboards
Mark T Ziolo
Ohio State University
$3,877,598
Attributed
$6,332,204
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $623.7K · FY2006–23$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,332,204 · 6
By mechanism
R01$4,858,052 · 2
K02$520,830 · 1
R56$450,310 · 1
R21$423,500 · 1
F32$79,512 · 1
Top collaborators
- Kristin I Stanford6 shared
- Paul Martin Coen5 shared
- Jonathan Paul Davis2 shared
Most similar at Ohio State University
Same institution · by research overlap
- Kristin I Stanford$6,188,806
- Jonathan Paul Davis$6,654,562
- Jack A Rall$2,202,329
- Svetlana B Tikunova$1,044,274
- Paulus Ml Janssen$9,312,933
Others in their field
Top investigators on “Heart”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Judith S Hochman · New York University School Of Medicine$118,439,174
- Deborah Nickerson · University Of Washington$86,844,068
- Rebecca Montalvan · Westat, Inc.$86,600,000
Research focus
HeartSignal TransductionResponseHeart FunctionInnovationCardiacPlayCollaborationsNitric OxideFunctional DisorderProteinsAdrenergic AgentsAction PotentialsAgingAdrenergicCellsIn VivoEnzymesDrug DevelopmentAgedEchocardiographyHeart DiseasesCardiac MyocytesCardiovascular Diseases
Grant awards (20)
BAT as a therapeutic for the metabolic and cardiac dysfunction with senescence.$579,592
R01 · FY2023 · AG
BAT as a therapeutic for the metabolic and cardiac dysfunction with senescence.$601,884
R01 · FY2022 · AG
BAT as a therapeutic for the metabolic and cardiac dysfunction with senescence.$599,696
R01 · FY2021 · AG
BAT as a therapeutic for the metabolic and cardiac dysfunction with senescence.$623,704
R01 · FY2020 · AG
BAT as a therapeutic for the metabolic and cardiac dysfunction with senescence.$621,676
R01 · FY2019 · AG
BAT as a therapeutic for the metabolic and cardiac dysfunction with senescence$450,310
R56 · FY2018 · AG
A novel inotropic gene therapy approach for aging induced cardiac dysfunction$192,500
R21 · FY2017 · AG · contact PI
A novel inotropic gene therapy approach for aging induced cardiac dysfunction$231,000
R21 · FY2016 · AG · contact PI
Nitric oxide signaling in healthy and diseased cardiac myocytes$104,166
K02 · FY2013 · HL · contact PI
Nitric oxide signaling in healthy and diseased cardiac myocytes$104,166
K02 · FY2012 · HL · contact PI
Nitric oxide signaling in healthy and diseased cardiac myocytes$104,166
K02 · FY2011 · HL · contact PI
NOS1/NOS3 Functional Effects on Cardiac Myocyte Function$364,125
R01 · FY2010 · HL · contact PI
Nitric oxide signaling in healthy and diseased cardiac myocytes$104,166
K02 · FY2010 · HL · contact PI
NOS1/NOS3 Functional Effects on Cardiac Myocyte Function$364,125
R01 · FY2009 · HL · contact PI
Nitric oxide signaling in healthy and diseased cardiac myocytes$104,166
K02 · FY2009 · HL · contact PI
NOS1/NOS3 Functional Effects on Cardiac Myocyte Function$364,125
R01 · FY2008 · HL · contact PI
NOS1/NOS3 Functional Effects on Cardiac Myocyte Function$364,125
R01 · FY2007 · HL · contact PI
NOS1/NOS3 Functional Effects on Cardiac Myocyte Function$375,000
R01 · FY2006 · HL · contact PI
NITRIC OXIDE AND SARCOPLASMIC RETICULUM CA TRANSPORT$41,996
F32 · FY2001 · HL
NITRIC OXIDE AND SARCOPLASMIC RETICULUM CA TRANSPORT$37,516
F32 · FY2000 · HL